We are live on ! Find out more
AR

Advisory Research Portfolio holdings

AUM $813M
1-Year Est. Return 36.71%
This Fund
S&P 500
This Quarter Est. Return
+0.62%
1 Year Est. Return
+36.71%
3 Year Est. Return
+123.04%
5 Year Est. Return
+262.63%
10 Year Est. Return
+840.35%
AUM
$720M
AUM Growth
-$59.6M
Cap. Flow
-$36.5M
Cap. Flow %
-5.06%
Top 10 Hldgs %
17.21%
Holding
510
New
74
Increased
122
Reduced
203
Closed
86

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$4.08M
2
JBTM
JBT Marel
JBTM
+$3.91M
3
PRSU
Pursuit Attractions and Hospitality Inc
PRSU
+$3.66M
4
NOG icon
Northern Oil and Gas
NOG
+$3.45M
5
DVN icon
Devon Energy
DVN
+$3.09M

Top Sells

Rank Stock Value
1
DEN
Denbury Inc.
DEN
+$7.07M
2
RS icon
Reliance Steel & Aluminium
RS
+$5.93M
3
CHX
ChampionX
CHX
+$4.74M
4
ACN icon
Accenture
ACN
+$4.11M
5
ONON icon
On Holding
ONON
+$3.96M

Sector Composition

Rank Sector Weight
1 Technology 21.49%
2 Consumer Discretionary 17.64%
3 Industrials 15.79%
4 Healthcare 11.67%
5 Financials 10.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICE icon
451
Intercontinental Exchange
ICE
$82.4B
– –
-2,337
Closed -$264K
INSP icon
452
Inspire Medical Systems
INSP
$1.42B
– –
-2,907
Closed -$944K
INTC icon
453
Intel
INTC
$466B
– –
-9,850
Closed -$329K
INTA icon
454
Intapp
INTA
$2.12B
– –
-46,778
Closed -$1.96M
IPGP icon
455
IPG Photonics
IPGP
$3.89B
– –
-10,169
Closed -$1.38M
IRM icon
456
Iron Mountain
IRM
$38.2B
– –
-16,901
Closed -$960K
IRWD icon
457
Ironwood Pharmaceuticals
IRWD
$611M
– –
-30,854
Closed -$328K
JCI icon
458
Johnson Controls International
JCI
$87.5B
– –
-3,998
Closed -$272K
LFST icon
459
Lifestance Health
LFST
$4.16B
– –
-124,188
Closed -$1.13M
LOVE icon
460
LoveSac
LOVE
$239M
– –
-55,158
Closed -$1.49M
LQDA icon
461
Liquidia Corp
LQDA
$7.67B
– –
-40,763
Closed -$320K
MRVL icon
462
Marvell Technology
MRVL
$174B
– –
-5,529
Closed -$331K
NEM icon
463
Newmont
NEM
$98.2B
– –
-5,955
Closed -$254K
NOC icon
464
Northrop Grumman
NOC
$77B
– –
-568
Closed -$259K
NUS icon
465
Nu Skin
NUS
$247M
– –
-9,453
Closed -$314K
PACB icon
466
Pacific Biosciences
PACB
$422M
– –
-23,455
Closed -$312K
PGR icon
467
Progressive
PGR
$124B
– –
-2,672
Closed -$354K
PIII icon
468
P3 Health Partners
PIII
$32M
– –
-2,337
Closed -$349K
PNW icon
469
Pinnacle West Capital
PNW
$12.9B
– –
-8,407
Closed -$685K
PRTA icon
470
Prothena Corp
PRTA
$458M
– –
-22,039
Closed -$1.5M
PRU icon
471
Prudential Financial
PRU
$41.7B
– –
-2,928
Closed -$258K
PRVA icon
472
Privia Health
PRVA
$3.21B
– –
-17,214
Closed -$449K
RELX icon
473
RELX
RELX
$60.1B
– –
-17,127
Closed -$573K
RTX icon
474
RTX Corp
RTX
$287B
– –
-3,473
Closed -$340K
RXRX icon
475
Recursion Pharmaceuticals
RXRX
$1.57B
– –
-135,683
Closed -$1.01M
17 18
19
20 21

Similar funds

VFG
Victory Financial Group Austin, Texas $814M AUM 18.17% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
UAG
United Advisor Group Cincinnati, Ohio $811M AUM 18.32% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $816M AUM 34.73% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return

Advisory Research's Q3 2023 Portfolio in Review

As of Q3 2023, Advisory Research held 510 positions worth $720M, down 7.6% from $780M the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Advisory Research withdrew a net $36.5M in Q3 2023, closing 86 positions and reducing 203 holdings. Its most notable exit was Livent Corporation, an estimated $2.81M position sold in full.

By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 22% a quarter earlier, followed by Consumer Discretionary and Industrials.

Against the trend, Advisory Research opened a new position in JBT Marel worth $3.67M.

  • Advisory Research's largest Q3 2023 buy was JBT Marel: 34,900 shares worth $3.67M.
  • Advisory Research added most to GSK in Q3 2023, an estimated $4.08M increase.
  • Advisory Research's biggest Q3 2023 reduction was Denbury Inc., cutting an estimated $7.07M.
  • Advisory Research fully exited Livent Corporation in Q3 2023, selling an estimated $2.81M.
  • Advisory Research's ten largest holdings make up 17% of its $720M portfolio in Q3 2023.
  • Advisory Research opened 74 new positions and closed 86 in Q3 2023.
  • Advisory Research's portfolio value fell 7.6% quarter-over-quarter to $720M.

Based on Advisory Research's 13F filing for Q3 2023, filed 13 Nov 2023.